Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
新泽西州帕西帕尼，2024年11月12日（环球新闻社） - pacira biosciences公司（纳斯达克股票代码：PCRX）今天宣布将参加以下两场医疗保健会议上的分析师团队讨论会：
- Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).
- 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET.
- 杰富瑞伦敦医疗保健会议将于11月19日星期二GMT时间下午3:00（美国东部时间上午10:00）举行。
- 第36届派杰投资医疗保健会议将于12月3日星期二下午1:00（美国东部时间）举行。
Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.
会议现场音频可以通过访问公司网站investor.pacira.com上的“活动”页面进行查看。网站还将提供这些活动后两周内的网络直播重播。
About Pacira
Pacira BioSciences delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, interscalene brachial plexus nerve block in adults, sciatic nerve block in the popliteal fossa in adults, and adductor canal block in adults for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioverao, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit .
关于Pacira
pacira biosciences提供创新的非阿片类疼痛疗法，以改善患者生活。Pacira拥有三种处于商业阶段的非阿片类治疗产品：EXPAREL（布比卡因脂质体注射悬液），一种长效局部镇痛药，目前已获批用于成人的渗入、筋膜平面阻滞、肩胛间神经丛阻滞、坐骨神经丛阻滞、股四头肌管阻滞术后疼痛管理；ZILRETTA（曲安特龙缓释注射液），一种缓释关节内注射剂，适用于骨关节炎膝关节疼痛治疗；iovera，一种新颖的手持设备，通过精确控制的冷温度剂量作用于靶神经，提供即时、长效的无药疗法疼痛控制。该公司还在推进PCRX-201的开发，这是一种新颖的局部基因治疗，具有治疗骨关节炎等常见疾病的潜力。要了解有关Pacira的更多信息，请访问。
CONTACT: Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
联系方式：公司联系人：
pacira biosciences 公司
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com
